抗血小板药物可有效减少血栓事件的发生,但增加胃肠道出血风险,通常加用质子泵抑制剂(PPI)来避免抗血小板药物所导致的黏膜损害。PPI具有与氯吡格雷相同的肝脏的代谢途径,可能降低氯吡格雷的抗血小板疗效并导致发生不良心血管事件的危险增加。氯吡格雷与PPI联合应用是否影响抗血小板药物治疗效果,目前对这一现象尚无定论,该文就氯吡格雷与PPI相互作用的机制和临床研究进展作一综述。 Anti-platelet drugs can effectively reduce the incidence of thrombotic events, but increase the risk of gastrointestinal bleeding, proton pump inhibitor (PPI) is usually added to avoid mucosal damage caused by anti-platelet drugs. PPI has the same liver metabolic pathway as clopidogrel and may reduce the antiplatelet effect of clopidogrel and lead to an increased risk of developing adverse cardiovascular events. The combination of clopidogrel and PPI affect the anti-platelet drug treatment effect, at present this phenomenon is not conclusive, the mechanism of clopidogrel and PPI interaction and clinical research are reviewed.